Document Detail


Emerging drugs for managing kidney disease in patients with diabetes.
MedLine Citation:
PMID:  23330907     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: The need for new approaches to manage the increasing numbers of patients with diabetes and their burden of complications is urgent. Of these, chronic kidney disease imposes some of the highest costs, both in dollars and in terms of human suffering. In individuals with diabetes, the presence and severity of kidney disease adversely affects their well-being, contributes to disease morbidity and increases their risk of a premature death.
AREAS COVERED: To collect information for the strategies previously or currently under investigation for managing kidney disease in patients with diabetes, a literature search was performed through the search engines PubMed and ClinicalTrials.gov.
EXPERT OPINION: Despite advancing knowledge on the pathogenesis of diabetic kidney disease, and promising effects in experimental models, at present there are no new drugs that come close to providing the solutions we desire for our patients. Even when used in combination with standard care, renal complications are at best only modestly reduced, at the considerable expense of additional pill burden and exposure to serious off-target effects. Some of the most exciting advances over the last decade, including thiazolidinediones, direct renin inhibitors, endothelin antagonists and most recently bardoxolone methyl have all fallen at this last hurdle. Better targeted ('smarter') drugs appear to be the best hope for renoprotective therapy.
Authors:
Merlin C Thomas
Related Documents :
25086687 - Effect of normobaric hyperoxic therapy on tissue oxygenation in diabetic feet: a pilot ...
16842487 - Assessment of diabetes screening by general practitioners in france: the epidia study.
24625797 - Severe diabetic retinal disease and dementia risk in type 2 diabetes.
24401727 - Treatment of antipsychotic-associated obesity with a glp-1 receptor agonist--protocol f...
20711547 - Metabolic syndrome: comparison of diagnosis criteria.
7888827 - Management of hereditary hemochromatosis.
Publication Detail:
Type:  Journal Article; Review     Date:  2013-01-21
Journal Detail:
Title:  Expert opinion on emerging drugs     Volume:  18     ISSN:  1744-7623     ISO Abbreviation:  Expert Opin Emerg Drugs     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-03-01     Completed Date:  2013-08-21     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101135662     Medline TA:  Expert Opin Emerg Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  55-70     Citation Subset:  IM    
Affiliation:
Baker IDI Heart and Diabetes Institute, St Kilda Rd Central, PO Box 6492, Melbourne, VIC 8008, Australia. mthomas@bakeridi.edu.au
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Clinical Trials as Topic
Diabetic Nephropathies / drug therapy*,  metabolism,  prevention & control
Drugs, Investigational / pharmacology,  therapeutic use*
Endothelins / antagonists & inhibitors,  metabolism
Humans
Hypoglycemic Agents / pharmacology,  therapeutic use*
Kidney / drug effects*,  metabolism
Protective Agents / pharmacology,  therapeutic use*
Renal Insufficiency, Chronic / drug therapy*,  metabolism,  prevention & control
Renin / antagonists & inhibitors,  metabolism
Chemical
Reg. No./Substance:
0/Drugs, Investigational; 0/Endothelins; 0/Hypoglycemic Agents; 0/Protective Agents; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A proposal for evaluating the validity of holistic-based admission processes.
Next Document:  Structure-Based Design, Synthesis of C-1 and C-4 Modified Analogs of Zanamivir as Neuraminidase Inhi...